Source comparison
Tesamorelin + Ipamorelin Blend Interactions: Peptide Comparison
Before selecting a peptide protocol, understanding how different compounds interact at the receptor level determines both efficacy and safety. The table below compares tesamorelin + ipamorelin blend interactions against alternative GH-modulating peptide combin
This comparison does not assign a generated winner or score.
- Before selecting a peptide protocol, understanding how different compounds interact at the receptor level determines both efficacy and safety. The table below compares tesamorelin + ipamorelin blend interactions against alternative GH-modulating peptide combinations.
- Tesamorelin + Ipamorelin
- GHRH-R + GHS-R1a dual activation
- 2.5–3.5× GH peak vs monotherapy
- Minimal. Neither compound elevates significantly
- Both within 20–40 min
- Gold standard for clean, pulsatile GH elevation without metabolic side effects
- CJC-1295 No DAC + Ipamorelin
- GHRH analog + GHS-R1a agonist
- 2–3× GH peak, similar to tesamorelin blend
- Minimal
- Both within 30–60 min
- Comparable efficacy, slightly shorter half-life than tesamorelin. More frequent dosing
- Sermorelin + Hexarelin
- GHRH analog + broad ghrelin mimetic
- 2–2.5× GH peak, but receptor desensitization after 2–4 weeks
- Moderate. Hexarelin elevates cortisol 20–30%
- Both within 30 min
- Effective short-term but unsustainable. Hexarelin desensitizes GHS-R1a
- MK-677 (monotherapy)
- Oral GHS-R1a agonist
- None. Single pathway
- Moderate appetite stimulation, mild cortisol elevation
- Daily oral dosing
- Convenient oral administration but lacks dual-pathway synergy
- Tesamorelin + GHRP-2
- GHRH-R + broad ghrelin receptor activation
- 2.5–3× GH peak, but less selective
- Significant. GHRP-2 elevates cortisol and prolactin
- Effective but cortisol impact limits long-term use